Fennec Pharmaceuticals Inc. (FENC)
FENC trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1211583/000110465926036182/0001104659-26-036182-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | FENC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001211583 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | BC |
| Canadian listing | TSX: FRX |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $44.6M |
| Net income | -$9.7M |
| Operating income | -$6.3M |
| Net margin | -21.8% |
| Operating margin | -14.1% |
| Revenue growth | -6.1% |
| Cash | $36.8M |
| Total assets | $70.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 10.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $48.7M cash; operating cash flow $787K a quarter. | Report 2026-09-30 |
| Shares outstanding | 35,305,117 (2026-11-10); 28,116,829 a year earlier; 26,634,676 three years earlier. | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2025-11-18 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Haskell & White LLP, Irvine, California, United States | PCAOB Form AP 2026-05-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $12.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $19.6M | $4.6M | $6.7M | $48.7M | No debt tags | $66.4M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $17.9M | $2.0M | $50K | $41.2M | No debt tags | $59.2M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $15.1M | $201K | $2.4M | $40.2M | No debt tags | $51.0M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $13.8M | -$4.8M | -$6.0M | $36.8M | No debt tags | $44.6M | 10-K 2026-03-27 |
| Q3 2025 2025-09-30 | $12.5M | -$638K | $1.5M | $21.9M | $19.4M | $38.8M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $9.7M | -$3.2M | -$3.7M | $18.7M | $19.4M | $33.3M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $8.8M | -$1.2M | -$4.3M | $22.7M | $19.4M | $30.9M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $7.9M | -$2.0M | -$1.5M | $26.6M | $19.3M | $47.5M | 10-K 2026-03-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-11-18 |
| Latest annual report | 10-K | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-09-17 |
| Latest proxy | DEF 14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 858 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +18.5% |
| 1 month | +14.1% |
| 3 months | -3.6% |
| Year to date | +50.9% |
| 1 year | +51.1% |
| From 52-week high | -9.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CADL | Candel Therapeutics Inc. | $5.81 | -6.29% | $455.8M |
| TVGN | Tevogen Inc. | $6.22 | +3.67% | $422.2M |
| RGNX | REGENXBIO Inc. | $7.32 | -4.19% | $484.0M |
| TECX | Tectonic Therapeutic Inc. | $20.98 | -0.76% | $418.5M |
| IRLA | IRulya Therapeutics Inc. | $37.36 | -6.13% | $405.0M |
| SLBT | SL Science Holding Limited | $0.7195 | -3.42% | $403.5M |
| ETRA | Electra Therapeutics Inc. | $8.31 | -6.00% | $522.4M |
| ENTX | Entera Bio Ltd. | $3.02 | -2.89% | $525.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier